Kurzfassung

An open label, randomized, two-arm phase III sof Nivolumab in combination with Ipilimumab versus extreme study regimen (Cetuximab + Cisplatin/Carboplatin + Fluorouracil) as first-line therapy in recurrent or metastatic squamous cell carcinoma of the head and neck (SCCHN)